Division of Hematology and Oncology, Department of Medicine, George Washington University Medical Center, Washington, DC, USA.
Ther Adv Med Oncol. 2013 Jan;5(1):25-40. doi: 10.1177/1758834012458137.
The past few years have brought increasing advances in the therapeutic management of metastatic castration-resistant prostate cancer with the approval of several agents, including vaccine therapy with sipuleucel-T, second-line chemotherapy with cabazitaxel, the bone-targeted pharmaceutical denosumab, and the novel antiandrogen therapy abiraterone acetate. There are ongoing developments with other agents in the pipeline such as MDV3100 and alpharadin that have shown promising results. This review describes the clinical trials that brought about the drug approvals of various agents and offers some insights regarding a rational approach to optimal treatment sequencing for these drugs since national guidelines are currently lacking.
过去几年，随着几种药物的批准，转移性去势抵抗性前列腺癌的治疗管理取得了越来越多的进展，包括 sipuleucel-T 的疫苗治疗、卡巴他赛的二线化疗、骨靶向药物地舒单抗和新型抗雄激素治疗醋酸阿比特龙。其他药物如 MDV3100 和 alpharadin 也在研发中，显示出了有前景的结果。本文综述了带来各种药物批准的临床试验，并就这些药物的最佳治疗顺序的合理方法提供了一些见解，因为目前缺乏国家指南。
